Capricor Therapeutics (NASDAQ:CAPR) Shares Gap Up on Better-Than-Expected Earnings

Capricor Therapeutics Inc (NASDAQ:CAPR) gapped up prior to trading on Thursday after the company announced better than expected quarterly earnings. The stock had previously closed at $12.22, but opened at $12.56. Capricor Therapeutics shares last traded at $13.79, with a volume of 401,510 shares traded.

The biotechnology company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.31) by $0.15. Capricor Therapeutics had a negative return on equity of 112.95% and a negative net margin of 146.86%. The business had revenue of $11.13 million for the quarter, compared to analyst estimates of $9.87 million.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on the company. Cantor Fitzgerald restated an “overweight” rating and set a $30.00 price target on shares of Capricor Therapeutics in a research report on Thursday. HC Wainwright reaffirmed a “buy” rating and issued a $77.00 target price on shares of Capricor Therapeutics in a research report on Monday. One equities research analyst has rated the stock with a sell rating and six have given a buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $34.50.

Institutional Investors Weigh In On Capricor Therapeutics

A number of large investors have recently modified their holdings of CAPR. California State Teachers Retirement System increased its holdings in Capricor Therapeutics by 1,653.0% in the fourth quarter. California State Teachers Retirement System now owns 32,237 shares of the biotechnology company’s stock valued at $445,000 after buying an additional 30,398 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new position in shares of Capricor Therapeutics during the 4th quarter worth about $462,000. Voloridge Investment Management LLC purchased a new position in shares of Capricor Therapeutics in the 4th quarter valued at about $1,678,000. Woodline Partners LP acquired a new stake in shares of Capricor Therapeutics during the 4th quarter worth about $8,693,000. Finally, Two Sigma Investments LP lifted its stake in Capricor Therapeutics by 223.6% during the fourth quarter. Two Sigma Investments LP now owns 119,047 shares of the biotechnology company’s stock worth $1,643,000 after purchasing an additional 82,254 shares during the last quarter. 21.68% of the stock is owned by hedge funds and other institutional investors.

Capricor Therapeutics Stock Up 13.8 %

The stock has a fifty day moving average of $14.05 and a 200-day moving average of $14.50. The stock has a market capitalization of $632.21 million, a price-to-earnings ratio of -13.20 and a beta of 4.10.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.